In this interview we discuss results of the PlanB trial, which showed that use of the 21-gene recurrence score, Oncotype DX, can identify patients with early breast cancer who likely do not need chemotherapy.
Oleg Gluz, MD
Advertisement
Articles by Oleg Gluz, MD
Advertisement
Latest Updated Articles
Multigene Testing to Forgo Chemotherapy in Early Breast CancerPublished: April 25th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Could Scorpion Venom Component Play a Role in Glioblastoma Management?
2
How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research
3
What Were The Most Impactful GU Oncology Data From ESMO 2025?
4
FDA Approves Abbreviated NDA for Dasatinib Tablets in Leukemia Indications
5
